Evidence map›Paper›PMID 41476584›Full record

ArticleFrontiers in oncology2025

Risk stratification for early-stage NSCLC progression: a federated learning framework with large-small model synergy.

Zijun Huang, Bao Feng, Yehang Chen, Liebin Huang, Yuan Chen, Xiaobei Duan, Xiaojuan Chen, Huan Lin, Kunwei Li, Yuping Li and 4 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zijun Huang *School of Electronic Engineering and Automation, Guilin University of Electronic Technology, Guilin, China.
Bao Feng *Laboratory of Intelligent Detection and Information Processing, Guilin University of Aerospace Technology, Guilin, China.
Yehang Chen *Laboratory of Intelligent Detection and Information Processing, Guilin University of Aerospace Technology, Guilin, China.
Liebin HuangDepartment of Radiology, Jiangmen Central Hospital, Jiangmen, China.
Yuan ChenDepartment of Gynecology, Jiangmen Central Hospital, Jiangmen, China.
Xiaobei DuanNuclear Medicine Department, Jiangmen Central Hospital, Jiangmen, China.
Xiaojuan ChenDepartment of Radiology, Jiangmen Central Hospital, Jiangmen, China.
Huan LinDepartment of Radiology, Guangdong General Hospital, Guangzhou, China.
Kunwei LiDepartment of Radiology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Yuping LiSchool of Electronic Engineering and Automation, Guilin University of Electronic Technology, Guilin, China.
Qiong LiDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xiaohong RuanDepartment of Gynecology, Jiangmen Central Hospital, Jiangmen, China.
Xiangmeng ChenDepartment of Radiology, Jiangmen Central Hospital, Jiangmen, China.
Wansheng LongJiangmen Key Laboratory of Artificial Intelligence in Medical Image Computation and Application, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Accurate prediction of non-small cell lung cancer (NSCLC) progression is crucial for guiding clinical decision-making and alleviating patients' psychological burden. Overtreatment risks unnecessary trauma for low-risk patients, while undertreatment may delay timely intervention for high-risk cases, worsening prognosis. This study aimed to develop a precise risk stratification system. The aim of this study is to develop an accurate risk stratification system to improve prediction accuracy and stratified management. To validate the proposed framework's versatility and robustness, we conducted multiple cross-task validation experiments. Materials and methods: This retrospective study included 926 patients with resected stage I-IIA NSCLC who underwent radical surgery at four centers between January 2014 and September 2019. A multi-center intelligent risk stratification model FesCPI (Federated cross-scale Common-Personal-Interactive learning) was developed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Model stability was assessed with five-fold cross-validation, and clinical utility was further validated through decision curve analysis (DCA). Additionally, cross-task experiments for gastric cancer and endometrial cancer were conducted to validate the model's performance. Results: FedCPI consistently outperformed clinical stratification ((DeLong test, p < 0.05)) and federated learning baselines across multicenter tasks. In early-stage NSCLC, it achieved AUCs up to 0.9255 and ACCs up to 0.8909, with 4.23-15.95% gains over competing models. The framework continues to demonstrate outstanding performance in various tasks, including predicting gastric cancer recurrence and endometrial cancer infiltration, thereby validating the effectiveness of this methodology. Feature analyses confirmed complementary roles of VFMs and ResNet18, while ablation studies showed that both Large-Small Model Feature Decomposition and Fusion (LMSF) and Federated Adaptive Communication Mechanism (FACM) were indispensable for optimal performance. Conclusion: Our findings suggest that the DL(deep learning)-based FedCPI framework provides a non-invasive, accurate, and reliable tool for early-stage lung cancer risk stratification. Furthermore, the methodology demonstrated excellent performance in independent validation experiments for clinical tasks involving gastric cancer and endometrial cancer. By improving diagnostic precision, this approach has the potential to optimize clinical decision-making and reduce the burden of overtreatment for patients.

Indexed as

deep learningfederated communicationlarge-small model synergymultiple cross-task validationNSCLC

Identifiers

PMID41476584
PMCPMC12750462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.